Search

19 NO UV EL LE S M AG AZ IN E NOUVELLE C. Beaudoin, S. Maquaire, J. Allemand, C. Lours-Calet, G. Veyssiere, M. Manin, L. Morel : CNRS UMR 6247/ Clermont Universite/INSERM U931, Campus Universitaire des Cezeaux, 24, avenue des Landais, 63177 Aubiere Cedex, France. Laurent.MOREL@univ-bpclermont.fr L. Leotoing : Departement d’Hematologie, Inserm U567, Institut Cochin, 24, rue du Faubourg Saint-Jacques, 75014 Paris, France. NPM : un nouvel acteur dans le cancer de la prostate ?

The chaperone nucleophosmin (NPM1) is over-expressed in the epithelial compartment of prostate tumours compared to adjacent healthy epithelium and may represent one of the key actors that support the neoplastic phenotype of prostate adenocarcinoma cells. Yet, the mechanisms that underlie NPM1 mediated phenotype remain elusive in the prostate. To better understand NPM1 functions in prostate cancer cells, we sought to characterize its impact on prostate cancer cells behaviour and decipher the mechanisms by which it may act. Here we show that NPM1 favors prostate tumour cell migration, invasion and colony forming. Furthermore, knockdown of NPM1 leads to a decrease in the growth of LNCaP-derived tumours grafted in Nude mice in vivo. Such oncogenic-like properties are found in conjunction with a positive regulation of NPM1 on the ERK1/2 (Extracellular signal-Regulated Kinases 1/2) kinase phosphorylation in response to EGF (Epidermal Growth Factor) stimulus, which is critical for prostate cancer progression following the setting of an autonomous production of the growth factor. NPM1 could then be a target to switch off specifically ERK1/2 pathway activation in order to decrease or inhibit cancer cell growth and migration.